MLYS Mineralys Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
0.681
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Steve Cohen's Point72 Exits Mineralys Therapeutics Ahead of Key FDA Decision
In a significant portfolio shift, Steve Cohen's Point72 Asset Management fully exited its position in Mineralys Therapeutics (MLYS) during the second quarter...
Deerfield Management Discloses New $106.8M Stake in Mineralys Therapeutics
In a new 13F filing, healthcare-focused investment firm Deerfield Management revealed it has established a significant position in Mineralys Therapeutics...